Category Archives: Pharmaceutical Litigation

Product liability lawyers on pharmaceutical litigation involving dangerous and recalled medication and medical devices.

Is EpiPen Price Gouging Going to Lead to Lawsuits?

There is much outrage over the increase in EpiPen pricing from the internet as well as from the patients that need the life-saving medication. The EpiPen device is used to stop life-threatening allergic reactions to common allergens such as bee stings, peanuts or other types of foods. The auto-injector device is stored in a convenient, small container and is injected into the patient’s thigh to stop a severe allergic reaction, such as anaphylaxis. The EpiPen was less than $100 and was easily available to both families and schools with children who were susceptible to allergic reactions. However, Mylan Pharmaceutials Inc (MYL.O) acquired the auto-injector device in 2007 and hiked the price to more than $600 per EpiPen. This is why many parents, politicians and consumer groups are criticizing Mylan and accusing it of violating consumer protection laws. Mylan Pharmaceuticals is Facing Lawsuits, Subpoenas and More Now, a lawsuit was filed…
Read More »

Posted in Pharmaceutical Litigation | Tagged | Leave a comment

Things You Didn’t Know About Dietary Supplements

In 2013 a transplant surgeon noticed the high number of people coming to her hospital with liver failure. She interviewed several of these patients and found that they had all taken the OxyElite Pro fitness supplement. The discovery led to a nationwide recall, and several lawsuits were filed, but it also exposed a danger that many Americans never suspected. Things You Didn’t Know About Dietary Supplements A study from the New England Journal of Medicine examined ER visits between 2004 and 2013, and discovered that 23,000 of those visits were associated with supplements. The study reported that 65 percent of those incidents involved supplements for weight loss, energy and sex drive, while around 30 percent of these visits involved vitamins and micronutrient pills. A quarter of those visits were by people ages 20 to 34, and almost another quarter of these visits were made by children who took supplements not…
Read More »

Posted in Pharmaceutical Litigation | Tagged | Leave a comment

Act Now For Xarelto Suits: Time Running Out

We have been keeping you up-to-date on the progress of the Xarelto multidistrict litigations, so we wanted to let you know that time is running out for any victims who have suffered injuries or lost loved ones due to this potentially harmful drug. Act Now For Xarelto Suits On September 17th, Judge Eldon Fallon signed a court order to begin selecting dates for the trials that would help speed the legal processes for the thousands of cases against the makers of Xarelto. These trials are called bellwether trials and they are expected to begin during the fall of 2016. That means that the multidistrict litigation could stop accepting new claims soon. How Will The Xarelto Multidistrict Litigation Work? There will be four trials that represent the interests of thousands of plaintiffs, and they will take place in Louisiana, Mississippi, and Texas. However, people from all over the country—including Florida natives—will…
Read More »

Posted in Pharmaceutical Litigation | Tagged | 2 Comments

Daiichi Sankyo Still Paying Fines for Benicar Doctor Kickbacks

Pharmaceutical giant Daiichi Sankyo has been ordered to pay another fine, the time in New Jersey, totaling $690,000. This comes after reaching a settlement in January to pay the U.S. federal government and Medicaid programs $39 million. This latest fine was an expansion of the previous settlement where a whistleblower accused the company of soliciting doctors to file false insurance claims for their drugs Azor, Benicar, Tribenzor and Welchol, all of which are derivative medications based on Benicar. Recently a multidistrict litigation (MDL) suit against Daiichi Sankyo was transferred to a judge in New Jersey as well. The MDL addresses the suffering and pain suffered by victims who took the prescription drug Benicar and its derivatives. The drug is currently being linked to sprue-like enteropathy and villous atrophy, two potentially fatal and long lasting intestinal conditions. Symptoms include: dehydration, chronic diarrhea, nausea, vomiting, and significant weight loss. Does My Doctor…
Read More »

Posted in Pharmaceutical Litigation | Tagged | Leave a comment

Xarelto Cases Fast Approaching Court Date

More news on our continued coverage of the Xarelto mass tort cases: June 11th is fast approaching, a significant day for members of the Xarelto federal multidistrict litigation. That day is when the attorneys for the plaintiffs get to present their scientific evidence to the court, and drive home their claims that they have linked bleeding complications to improperly disclosed Xarelto side effects. Xarelto is a blood-thinning drug, one of the newest, and it is used to treat medical conditions such as deep vein thrombosis and atrial fibrillation. The characteristics of such a drug raise the possibility of bleeding, or hemorrhaging, which can be fatal. Warfarin, the predecessor of Xarelto, holds the same risk, but can easily be reversed with the administration of Vitamin K. The lack of a reversing agent, as well as understated yet potentially dangerous side effects, has led to over 300 MDL lawsuits. Their day in…
Read More »

Posted in Pharmaceutical Litigation | Tagged | Leave a comment

Mass Tort Cases Rising Steadily in Philadelphia Xarelto Litigation

There is more information to report in this blog’s ongoing coverage of the lawsuits against the makers of the blood-thinner Xarelto. New case filings in the Philadelphia mass tort against Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and Bayer HealthCare Pharmaceuticals are gradually increasing as the Xarelto litigation moves forward in its early stages. After 50 new cases were filed in March, the total number of plaintiffs against Xarelto now stands at roughly 170. Attorneys involved in the litigation are unsure if the trend in filings will continue, but plaintiffs’ attorney Michael M. Weinkowitz did observe that, “there are a number of people out there holding back cases, sort of waiting to see where we go and where the MDL goes.” According the petition from the plaintiffs, by the end of 2012, Xarelto had already caused over 2,000 injuries and at least 151 deaths. The number of prescriptions written…
Read More »

Posted in Pharmaceutical Litigation | Leave a comment